Search results
Results from the WOW.Com Content Network
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [15]
The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries. [1]One of the biggest barriers to antidepressants coming to the market is that the medical insurance system in Japan is national, and the authorities are keen to contain a potentially explosive market for drugs like antidepressants that, from the Japanese ...
The Drug Enforcement Administration is increasing the production limit of Vyvanse and its generic equivalents by about 24% to address the ongoing global shortage of ADHD medications.
Vyvanse, also known as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, and ...
While methamphetamine is historically the most widely trafficked illegal drug in post-World War II Japan, marijuana, cocaine, and other prohibited substances are also present. Additionally, Japan's status as a developed economy and the presence of organized crime in Japan have made it a target of the international drug trade.
The Food and Drug Administration (FDA) approved the first generic versions of Vyvanse, a drug used to treat attention deficit/hyperactivity disorder (ADHD), a decision that comes amid a nationwide ...
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24.